FDA Scraps Biannual Biologics Inspections for Risk-Based Approach

Drug GMP Report
A A
The FDA is scrapping requirements that biologics be inspected at least every two years, moving instead to a risk-based schedule.

To View This Article:

Login

Subscribe To Drug GMP Report

Buy This Article Now

Add this article to your cart for $40.00